The IRE1α pathway in glomerular diseases: The unfolded protein response and beyond.

Frontiers in molecular medicine Pub Date : 2022-09-26 eCollection Date: 2022-01-01 DOI:10.3389/fmmed.2022.971247
José R Navarro-Betancourt, Andrey V Cybulsky
{"title":"The IRE1α pathway in glomerular diseases: The unfolded protein response and beyond.","authors":"José R Navarro-Betancourt, Andrey V Cybulsky","doi":"10.3389/fmmed.2022.971247","DOIUrl":null,"url":null,"abstract":"<p><p>Endoplasmic reticulum (ER) function is vital for protein homeostasis (\"proteostasis\"). Protein misfolding in the ER of podocytes (glomerular visceral epithelial cells) is an important contributor to the pathogenesis of human glomerular diseases. ER protein misfolding causes ER stress and activates a compensatory signaling network called the unfolded protein response (UPR). Disruption of the UPR, in particular deletion of the UPR transducer, inositol-requiring enzyme 1α (IRE1α) in mouse podocytes leads to podocyte injury and albuminuria in aging, and exacerbates injury in glomerulonephritis. The UPR may interact in a coordinated manner with autophagy to relieve protein misfolding and its consequences. Recent studies have identified novel downstream targets of IRE1α, which provide new mechanistic insights into proteostatic pathways. Novel pathways of IRE1α signaling involve reticulophagy, mitochondria, metabolism, vesicular trafficking, microRNAs, and others. Mechanism-based therapies for glomerulopathies are limited, and development of non-invasive ER stress biomarkers, as well as targeting ER stress with pharmacological compounds may represent a therapeutic opportunity for preventing or attenuating progression of chronic kidney disease.</p>","PeriodicalId":73090,"journal":{"name":"Frontiers in molecular medicine","volume":" ","pages":"971247"},"PeriodicalIF":0.0000,"publicationDate":"2022-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11285563/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in molecular medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/fmmed.2022.971247","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Endoplasmic reticulum (ER) function is vital for protein homeostasis ("proteostasis"). Protein misfolding in the ER of podocytes (glomerular visceral epithelial cells) is an important contributor to the pathogenesis of human glomerular diseases. ER protein misfolding causes ER stress and activates a compensatory signaling network called the unfolded protein response (UPR). Disruption of the UPR, in particular deletion of the UPR transducer, inositol-requiring enzyme 1α (IRE1α) in mouse podocytes leads to podocyte injury and albuminuria in aging, and exacerbates injury in glomerulonephritis. The UPR may interact in a coordinated manner with autophagy to relieve protein misfolding and its consequences. Recent studies have identified novel downstream targets of IRE1α, which provide new mechanistic insights into proteostatic pathways. Novel pathways of IRE1α signaling involve reticulophagy, mitochondria, metabolism, vesicular trafficking, microRNAs, and others. Mechanism-based therapies for glomerulopathies are limited, and development of non-invasive ER stress biomarkers, as well as targeting ER stress with pharmacological compounds may represent a therapeutic opportunity for preventing or attenuating progression of chronic kidney disease.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
肾小球疾病中的IRE1α通路:未折叠蛋白反应及其意义
内质网(ER)功能对蛋白质稳态(“蛋白稳态”)至关重要。足细胞(肾小球内脏上皮细胞)ER中的蛋白质错误折叠是人类肾小球疾病发病机制的重要因素。ER蛋白错误折叠导致ER应激,并激活称为未折叠蛋白反应(UPR)的补偿信号网络。UPR的破坏,特别是小鼠足细胞中UPR转换器、肌醇需要酶1α(IRE1α)的缺失,会导致衰老中的足细胞损伤和蛋白尿,并加剧肾小球肾炎的损伤。UPR可能以协调的方式与自噬相互作用,以减轻蛋白质错误折叠及其后果。最近的研究已经确定了IRE1α的新下游靶标,这为蛋白稳定途径提供了新的机制见解。IRE1α信号传导的新途径涉及食道、线粒体、代谢、膀胱运输、微小RNA等。肾小球疾病的基于机制的治疗是有限的,非侵入性ER应激生物标志物的开发,以及用药理学化合物靶向ER应激,可能代表着预防或减轻慢性肾脏疾病进展的治疗机会。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Editorial: Gene therapy and genome editing for metabolic liver disorders. An artificial transcription factor that activates potent interferon-γ expression in human Jurkat T Cells. Immune-checkpoint-inhibitor therapy directed against PD-L1 is tolerated in the heart without manifestation of cardiac inflammation in a preclinical reversible melanoma mouse model. Human-specific gene ARHGAP11B-potentially an additional tool in the treatment of neurodegenerative diseases? DeltaRex-G, tumor targeted retrovector encoding a CCNG1 inhibitor, for CAR-T cell therapy induced cytokine release syndrome.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1